Updated 06/21/2024

Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation — Crescendo

Chronic Myelogenous Leukemia (CML) Clinical Trial

Official title:
CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy

Status Completed

Clinical Trial Summary

This study on patient's compliance in clinical workaday life aims to assess and to improve CML treatment in Germany by means of adherence supporting measures and to increase adherence awareness by physicians and patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Myelogenous Leukemia (CML)
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Philadelphia Chromosome

Clinical Trial Details

NCT number	NCT01243489
Study type	Interventional
Source	Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Contact
Status	Completed
Phase	Phase 4
Start date	October 2010
Completion date	June 2018

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT02259348` - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation	Phase 2
	Recruiting	`NCT01351545` - A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
	Recruiting	`NCT01758042` - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders	N/A
	Completed	`NCT01885897` - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT	Phase 1/Phase 2
	Recruiting	`NCT05884333` - Cord Blood Transplant in Adults With Blood Cancers	Phase 2
	Completed	`NCT01735955` - Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study	Phase 4
	Completed	`NCT03959241` - TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)	Phase 3
	Terminated	`NCT01050764` - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells	Phase 1/Phase 2
	Terminated	`NCT00672152` - A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation	Phase 1
	Terminated	`NCT02200380` - A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs	Phase 2
	Completed	`NCT01768845` - Unrelated Umbilical Cord Blood (UBC)Transplantation	N/A
	Terminated	`NCT01663766` - Phase I Study of Milatuzumab for Graft Versus Host Disease	Phase 1
	Active, not recruiting	`NCT02730299` - Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS	Phase 3
	Completed	`NCT02226861` - Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation	Phase 1
	Completed	`NCT01413568` - Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies	Phase 1/Phase 2
	No longer available	`NCT04518644` - Nilotinib, for Patients With CML-CP or CML-AP